More China Woes For GSK? CFDA Wades Into Ozanezumab Controversy
This article was originally published in PharmAsia News
Executive Summary
Taking heat from critics amid a report that GSK may have conducted unethical trials for multiple sclerosis drug ozanezumab, China’s Center for Drug Evaluation conducts its own investigation.